Skip to main content

Table 4 Baseline patient demographic and disease characteristics in patients who evaluated for liver fibrosis

From: The effect of bone marrow-derived mesenchymal stem cell co-transplantation with hematopoietic stem cells on liver fibrosis alleviation and survival in patients with class III β-thalassemia major

Characteristics Mesenchymal patients (n = 47, 61%) Non-mesenchymal patients (n = 30, 39%) P value
Age (years), mean (P25–P75) 15.4 (10.94–16.81) 11.5 (5.73–15.13) 0.019
Patient sex, n (%) Male 27 (57.5%) 10 (33.3%) 0.039
Female 20 (42.5%) 20 (66.7%)
Donor sex, n (%) Male 25 (53.2%) 10 (38.5%) 0.228
Female 22 (46.8%) 16 (61.5%)
Sex match status, n (%) Sex-mismatch 26 (55.3%) 10 (38.5%) 0.168
Sex-match 21 (44.7%) 16 (61.5%)
ABO match status, n (%) ABO-mismatched 18 (39.1%) 7 (25%) 0.213
ABO-matched 28 (60.9%) 21 (75%)
Source of HSCT, n (%) BM 14 (29.8%) 14 (46.7%) 0.133
PB 33 (70.2%) 16 (53.3%)
Acute GvHD, n (%) No 21 (44.7%) 17 (56.7%) 0.305
Yes 26 (55.3%) 13 (43.3%)
Chronic GvHD, n (%) No 24 (51%) 16 (53.3%) 0.846
Yes 23 (49%) 14 (46.7%)
WBC (× 108/kg), mean (P25–P75) 8.38 (6.07–10.24) 7.13 (5.7–9.67) 0.732
MNC (× 108/kg), mean (P25–P75) 7.41 (3.3–8.11) 4.35 (2.71–8.22) 0.427
CD3 cell (× 106/kg), mean (P25–P75) 236.8 (76.02–335.6) 83.86 (62.3–269) 0.126
CD34 cell (× 106/kg), mean (P25–P75) 4.23 (2.6–6.42) 3.59 (2.8–8.07) 0.837
ANC engraftment (days), mean (P25–P75) 16.8 (14–21) 18.1 (15–24) 0.764
Platelets engraftment (days), mean (P25–P75) 25.8 (21–32) 35.6 (24–51) 0.273